About
Technology
Issues
FAQ
Links
Official Page
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.
